265. 脂肪萎縮症 Lipodystrophy Clinical trials / Disease details
臨床試験数 : 116 / 薬物数 : 170 - (DrugBank : 61) / 標的遺伝子数 : 26 - 標的パスウェイ数 : 97
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2013-004539-57-PL (EUCTR) | 30/01/2014 | 16/12/2013 | A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite) | A phase III, double-blind, placebo-controlled, randomized, three-arm parallel, study assessing efficacy and safety of 4 months of diosmin administration for the treatment of lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite) | lower extremity teleangiectasias and gynoid lipodystrophy (edematous fibrosclerotic panniculopathy commonly known as cellulite) MedDRA version: 17.0;Level: LLT;Classification code 10065339;Term: Cellulite;System Organ Class: 100000004858 MedDRA version: 17.0;Classification code 10043193;Term: Telangiectasis;System Organ Class: 100000004858;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Diosminex, 500 mg, tabletki powlekane INN or Proposed INN: diosmin Other descriptive name: DIOSMIN | ALIO MEDICA Sp. z o.o. | NULL | Not Recruiting | Female: yes Male: no | Phase 3 | Poland |